The potential role of proinflammatory and antiinflammatory cytokines in Alzheimer disease pathogenesis

References

• Passos, G.F., Figueiredo, C.P., Prediger, R.D., Silva, K.A., Siqueira, J.M., Duarte, F.S., Leal, P.C., et al. Involvement of phosphoinositide 3-kinase gamma in the neuro-inflammatory response and cognitive impairments induced by beta-amyloid 1-40 peptide in mice. Brain Behav Immun 2010, 24, 493–501.
   PubMed Web of Science ®Google Scholar
• Higuchi, M., Hatta, K., Honma, T., Hitomi, Y.H., Kambayashi, Y., Hibino, Y., Matsuzaki, I., et al. Association between altered systemic inflammatory interleukin-1beta and natural killer cell activity and subsequently agitation in patients with Alzheimer disease. Int J Geriatr Psychiatry 2010, 25, 604–611.
   PubMed Web of Science ®Google Scholar
• Vassar, R., Bennett, B.D., Babu-Khan, S., Kahn, S., Mendiaz, E.A., Denis, P., Teplow, D.B., et al. Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286, 735–741.
   PubMed Web of Science ®Google Scholar
• Craddock, T.J., Tuszynski, J.A., Chopra, D., Casey, N., Goldstein, L.E., Hameroff, S.R., Tanzi, R.E. The zinc dyshomeostasis hypothesis of Alzheimer’s disease. PLoS ONE 2012, 7, e33552.
   PubMed Web of Science ®Google Scholar
• Sarajärvi, T., Helisalmi, S., Antikainen, L., Mäkinen, P., Koivisto, A.M., Herukka, S.K., Haapasalo, A., et al. An association study of 21 potential Alzheimer’s disease risk genes in a Finnish population. J Alzheimers Dis 2010, 21, 763–767.
   PubMed Web of Science ®Google Scholar
• Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Small, G.W., Roses, A.D., et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993, 261, 921–923.
   PubMed Web of Science ®Google Scholar
• Strittmatter, W.J., Saunders, A.M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G.S., Roses, A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993, 90, 1977–1981.
   PubMed Web of Science ®Google Scholar
• Mahley, R.W., Huang, Y., Weisgraber, K.H. Putting cholesterol in its place: apoE and reverse cholesterol transport. J Clin Invest 2006, 116, 1226–1229.
   PubMed Web of Science ®Google Scholar
• Morgan, K. The three new pathways leading to Alzheimer’s disease. Neuropathol Appl Neurobiol 2011, 37, 353–357.
   PubMed Web of Science ®Google Scholar
• Naj, A.C., Jun, G., Beecham, G.W., Wang, L.S., Vardarajan, B.N., Buros, J., Gallins, P.J., et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet 2011, 43, 436–441.
   PubMed Web of Science ®Google Scholar
• Hollingworth, P., Harold, D., Sims, R., Gerrish, A., Lambert, J.C., Carrasquillo, M.M., Abraham, R., et al.; Alzheimer’s Disease Neuroimaging Initiative; CHARGE consortium; EADI1 consortium. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 2011, 43, 429–435.
   PubMed Web of Science ®Google Scholar
• Carrasquillo, M.M., Belbin, O., Hunter, T.A., Ma, L., Bisceglio, G.D., Zou, F., Crook, J.E., et al. Replication of CLU, CR1, and PICALM associations with alzheimer disease. Arch Neurol 2010, 67, 961–964.
   PubMedGoogle Scholar
• Lee, J.H., Cheng, R., Barral, S., Reitz, C., Medrano, M., Lantigua, R., Jiménez-Velazquez, I.Z., et al. Identification of novel loci for Alzheimer disease and replication of CLU, PICALM, and BIN1 in Caribbean Hispanic individuals. Arch Neurol 2011, 68, 320–328.
   PubMed Web of Science ®Google Scholar
• Olgiati, P., Politis, A., Malitas, P., Albani, D., Dusi, S., Polito, L., De Mauro, S., et al. APOE epsilon-4 allele and cytokine production in Alzheimer’s disease. Int J Geriatr Psychiatry 2010, 25, 338–344.
   PubMed Web of Science ®Google Scholar
• Lio, D., Licastro, F., Scola, L., Chiappelli, M., Grimaldi, L.M., Crivello, A., Colonna-Romano, G., et al. Interleukin-10 promoter polymorphism in sporadic Alzheimer’s disease. Genes Immun 2003, 4, 234–238.
   PubMed Web of Science ®Google Scholar
• Laws, S.M., Perneczky, R., Wagenpfeil, S., Müller, U., Förstl, H., Martins, R.N., Kurz, A., Riemenschneider, M. TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels. Hum Mutat 2005, 26, 29–35.
   PubMed Web of Science ®Google Scholar
• Vepsäläinen, S., Helisalmi, S., Mannermaa, A., Pirttilä, T., Soininen, H., Hiltunen, M. Combined risk effects of IDE and NEP gene variants on Alzheimer disease. J Neurol Neurosurg Psychiatr 2009, 80, 1268–1270.
   PubMed Web of Science ®Google Scholar
• Zou, F., Carrasquillo, M.M., Pankratz, V.S., Belbin, O., Morgan, K., Allen, M., Wilcox, S.L., et al. Gene expression levels as endophenotypes in genome-wide association studies of Alzheimer disease. Neurology 2010, 74, 480–486.
   PubMed Web of Science ®Google Scholar
• Farfara, D., Lifshitz, V., Frenkel, D. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer’s disease. J Cell Mol Med 2008, 12, 762–780.
   PubMed Web of Science ®Google Scholar
• McGeer, E.G., McGeer, P.L. Neuroinflammation in Alzheimer’s disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis 2010, 19, 355–361.
   PubMed Web of Science ®Google Scholar
• Lee, K.S., Chung, J.H., Choi, T.K., Suh, S.Y., Oh, B.H., Hong, C.H. Peripheral cytokines and chemokines in Alzheimer’s disease. Dement Geriatr Cogn Disord 2009, 28, 281–287.
   PubMed Web of Science ®Google Scholar
• Agostinho, P., Cunha, R.A., Oliveira, C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer’s disease. Curr Pharm Des 2010, 16, 2766–2778.
   PubMed Web of Science ®Google Scholar
• Mrak, R.E. Neuropathology and the neuroinflammation idea. J Alzheimers Dis 2009, 18, 473–481.
   PubMed Web of Science ®Google Scholar
• Shaftel, S.S., Kyrkanides, S., Olschowka, J.A., Miller, J.N., Johnson, R.E., O’Banion, M.K. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest 2007, 117, 1595–1604.
   PubMed Web of Science ®Google Scholar
• Yamamoto, M., Kiyota, T., Horiba, M., Buescher, J.L., Walsh, S.M., Gendelman, H.E., Ikezu, T. Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol 2007, 170, 680–692.
   PubMed Web of Science ®Google Scholar
• Tesseur, I., Zou, K., Esposito, L., Bard, F., Berber, E., Can, J.V., Lin, A.H., et al. Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer’s pathology. J Clin Invest 2006, 116, 3060–3069.
   PubMed Web of Science ®Google Scholar
• Villanueva, E.B., Little, J.P., Lambeau, G., Klegeris, A. Secreted phospholipase A(2) group IIA is a neurotoxin released by stimulated human glial cells. Mol Cell Neurosci 2012, 49, 430–438.
   PubMed Web of Science ®Google Scholar
• Rojo, L.E., Fernández, J.A., Maccioni, A.A., Jimenez, J.M., Maccioni, R.B. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer’s disease. Arch Med Res 2008, 39, 1–16.
   PubMed Web of Science ®Google Scholar
• Pabon, M.M., Bachstetter, A.D., Hudson, C.E., Gemma, C., Bickford, P.C. CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson’s disease. J Neuroinflammation 2011, 8, 9.
   PubMed Web of Science ®Google Scholar
• Michelucci, A., Heurtaux, T., Grandbarbe, L., Morga, E., Heuschling, P. Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-beta. J Neuroimmunol 2009, 210, 3–12.
   PubMed Web of Science ®Google Scholar
• Block, M.L. NADPH oxidase as a therapeutic target in Alzheimer’s disease. BMC Neurosci 2008, 9 Suppl 2, S8.
   PubMed Web of Science ®Google Scholar
• Shimizu, E., Kawahara, K., Kajizono, M., Sawada, M., Nakayama, H. IL-4-induced selective clearance of oligomeric beta-amyloid peptide(1-42) by rat primary type 2 microglia. J Immunol 2008, 181, 6503–6513.
   PubMed Web of Science ®Google Scholar
• Kanzawa, T., Sawada, M., Kato, K., Yamamoto, K., Mori, H., Tanaka, R. Differentiated regulation of allo-antigen presentation by different types of murine microglial cell lines. J Neurosci Res 2000, 62, 383–388.
   PubMed Web of Science ®Google Scholar
• Mantovani, A., Sozzani, S., Locati, M., Allavena, P., Sica, A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23, 549–555.
   PubMed Web of Science ®Google Scholar
• Mantovani, A. The chemokine system: redundancy for robust outputs. Immunol Today 1999, 20, 254–257.
   PubMedGoogle Scholar
• Bulgarelli, I., Tamiazzo, L., Bresciani, E., Rapetti, D., Caporali, S., Lattuada, D., Locatelli, V., Torsello, A. Desacyl-ghrelin and synthetic GH-secretagogues modulate the production of inflammatory cytokines in mouse microglia cells stimulated by beta-amyloid fibrils. J Neurosci Res 2009, 87, 2718–2727.
   PubMed Web of Science ®Google Scholar
• Reed-Geaghan, E.G., Savage, J.C., Hise, A.G., Landreth, G.E. CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J Neurosci 2009, 29, 11982–11992.
   PubMed Web of Science ®Google Scholar
• Chandler, D., Woldu, A., Rahmadi, A., Shanmugam, K., Steiner, N., Wright, E., Benavente-García, O., et al. Effects of plant-derived polyphenols on TNF-alpha and nitric oxide production induced by advanced glycation endproducts. Mol Nutr Food Res 2010, 54 Suppl 2, S141–S150.
   PubMed Web of Science ®Google Scholar
• Nah, S.S., Choi, I.Y., Yoo, B., Kim, Y.G., Moon, H.B., Lee, C.K. Advanced glycation end products increases matrix metalloproteinase-1, -3, and -13, and TNF-alpha in human osteoarthritic chondrocytes. FEBS Lett 2007, 581, 1928–1932.
   PubMed Web of Science ®Google Scholar
• Yan, S.D., Bierhaus, A., Nawroth, P.P., Stern, D.M. RAGE and Alzheimer’s disease: a progression factor for amyloid-beta-induced cellular perturbation? J Alzheimers Dis 2009, 16, 833–843.
   PubMed Web of Science ®Google Scholar
• Fang, F., Lue, L.F., Yan, S., Xu, H., Luddy, J.S., Chen, D., Walker, D.G., et al. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer’s disease. FASEB J 2010, 24, 1043–1055.
   PubMed Web of Science ®Google Scholar
• Arancio, O., Zhang, H.P., Chen, X., Lin, C., Trinchese, F., Puzzo, D., Liu, S., et al. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 2004, 23, 4096–4105.
   PubMed Web of Science ®Google Scholar
• Li, C., Zhao, R., Gao, K., Wei, Z., Yin, M.Y., Lau, L.T., Chui, D., Hoi Yu, A.C. Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer’s disease. Curr Alzheimer Res 2011, 8, 67–80.
   PubMed Web of Science ®Google Scholar
• Heneka, M.T., O’Banion, M.K., Terwel, D., Kummer, M.P. Neuroinflammatory processes in Alzheimer’s disease. J Neural Transm 2010, 117, 919–947.
   PubMed Web of Science ®Google Scholar
• Politis, A., Olgiati, P., Malitas, P., Albani, D., Signorini, A., Polito, L., De Mauro, S., et al. Vitamin B12 levels in Alzheimer’s disease: association with clinical features and cytokine production. J Alzheimers Dis 2010, 19, 481–488.
   PubMed Web of Science ®Google Scholar
• Ojala, J., Alafuzoff, I., Herukka, S.K., van Groen, T., Tanila, H., Pirttilä, T. Expression of interleukin-18 is increased in the brains of Alzheimer’s disease patients. Neurobiol Aging 2009, 30, 198–209.
   PubMed Web of Science ®Google Scholar
• Pellicanò, M., Bulati, M., Buffa, S., Barbagallo, M., Di Prima, A., Misiano, G., Picone, P., et al. Systemic immune responses in Alzheimer’s disease: in vitro mononuclear cell activation and cytokine production. J Alzheimers Dis 2010, 21, 181–192.
   PubMed Web of Science ®Google Scholar
• Speciale, L., Calabrese, E., Saresella, M., Tinelli, C., Mariani, C., Sanvito, L., Longhi, R., Ferrante, P. Lymphocyte subset patterns and cytokine production in Alzheimer’s disease patients. Neurobiol Aging 2007, 28, 1163–1169.
   PubMed Web of Science ®Google Scholar
• Oprica, M., Hjorth, E., Spulber, S., Popescu, B.O., Ankarcrona, M., Winblad, B., Schultzberg, M. Studies on brain volume, Alzheimer-related proteins and cytokines in mice with chronic overexpression of IL-1 receptor antagonist. J Cell Mol Med 2007, 11, 810–825.
   PubMed Web of Science ®Google Scholar
• Serretti, A., Olgiati, P., Politis, A., Malitas, P., Albani, D., Dusi, S., Polito, L., et al. Lack of association between interleukin-1 alpha rs1800587 polymorphism and Alzheimer’s disease in two Independent European samples. J Alzheimers Dis 2009, 16, 181–187.
   PubMed Web of Science ®Google Scholar
• Klimkowicz-Mrowiec, A., Marona, M., Wolkow, P., Maruszak, A., Styczynska, M., Barcikowska, M., Zekanowski, C., et al. Interleukin-1 gene -511 CT polymorphism and the risk of Alzheimer’s disease in a Polish population. Dement Geriatr Cogn Disord 2009, 28, 461–464.
   PubMed Web of Science ®Google Scholar
• Schmitt, T.L., Steiner, E., Klinger, P., Sztankay, A., Grubeck-Loebenstein, B. The production of an amyloidogenic metabolite of the Alzheimer amyloid beta precursor protein (APP) in thyroid cells is stimulated by interleukin 1 beta, but inhibited by interferon gamma. J Clin Endocrinol Metab 1996, 81, 1666–1669.
   PubMed Web of Science ®Google Scholar
• Shaftel, S.S., Griffin, W.S., O’Banion, M.K. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation 2008, 5, 7.
   PubMed Web of Science ®Google Scholar
• Wong, M.L., Bongiorno, P.B., Rettori, V., McCann, S.M., Licinio, J. Interleukin (IL) 1beta, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: pathophysiological implications. Proc Natl Acad Sci USA 1997, 94, 227–232.
   PubMed Web of Science ®Google Scholar
• Lemere, C.A. A beneficial role for IL-1 beta in Alzheimer disease? J Clin Invest 2007, 117, 1483–1485.
   PubMed Web of Science ®Google Scholar
• El Khoury, J., Luster, A.D. Mechanisms of microglia accumulation in Alzheimer’s disease: therapeutic implications. Trends Pharmacol Sci 2008, 29, 626–632.
   PubMed Web of Science ®Google Scholar
• Ting, K.K., Brew, B., Guillemin, G. The involvement of astrocytes and kynurenine pathway in Alzheimer’s disease. Neurotox Res 2007, 12, 247–262.
   PubMed Web of Science ®Google Scholar
• Guillemin, G.J., Smith, D.G., Smythe, G.A., Armati, P.J., Brew, B.J. Expression of the kynurenine pathway enzymes in human microglia and macrophages. Adv Exp Med Biol 2003, 527, 105–112.
   PubMed Web of Science ®Google Scholar
• Stone, T.W. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 1993, 45, 309–379.
   PubMed Web of Science ®Google Scholar
• Ting, K.K., Brew, B.J., Guillemin, G.J. Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer’s disease. J Neuroinflammation 2009, 6, 36.
   PubMed Web of Science ®Google Scholar
• Forlenza, O.V., Diniz, B.S., Talib, L.L., Mendonça, V.A., Ojopi, E.B., Gattaz, W.F., Teixeira, A.L. Increased serum IL-1beta level in Alzheimer’s disease and mild cognitive impairment. Dement Geriatr Cogn Disord 2009, 28, 507–512.
   PubMed Web of Science ®Google Scholar
• de Souza, D.F., Leite, M.C., Quincozes-Santos, A., Nardin, P., Tortorelli, L.S., Rigo, M.M., Gottfried, C., et al. S100B secretion is stimulated by IL-1beta in glial cultures and hippocampal slices of rats: Likely involvement of MAPK pathway. J Neuroimmunol 2009, 206, 52–57.
   PubMed Web of Science ®Google Scholar
• Seripa, D., Matera, M.G., Dal Forno, G., Gravina, C., Masullo, C., Daniele, A., Binetti, G., et al. Genotypes and haplotypes in the IL-1 gene cluster: analysis of two genetically and diagnostically distinct groups of Alzheimer patients. Neurobiol Aging 2005, 26, 455–464.
   PubMed Web of Science ®Google Scholar
• Hu, J.L., Li, G., Zhou, D.X., Zou, Y.X., Zhu, Z.S., Xu, R.X., Jiang, X.D., Zeng, Y.J. Genetic analysis of interleukin-1A C(-889)T polymorphism with Alzheimer disease. Cell Mol Neurobiol 2009, 29, 81–85.
   PubMed Web of Science ®Google Scholar
• Tachida, Y., Nakagawa, K., Saito, T., Saido, T.C., Honda, T., Saito, Y., Murayama, S., et al. Interleukin-1 beta up-regulates TACE to enhance alpha-cleavage of APP in neurons: resulting decrease in Abeta production. J Neurochem 2008, 104, 1387–1393.
   PubMed Web of Science ®Google Scholar
• Candiotti, K.A., Yang, Z., Morris, R., Yang, J., Crescimone, N.A., Sanchez, G.C., et al. Polymorphism in the interleukin-1 receptor antagonist gene is associated with serum interleukin-1 receptor antagonist concentrations and postoperative opioid consumption. Anesthesiology 2011, 114, 1162–1168.
   PubMed Web of Science ®Google Scholar
• Wang, K.C., Wang, S.J., Fan, L.W., Cai, Z., Rhodes, P.G., Tien, L.T. Interleukin-1 receptor antagonist ameliorates neonatal lipopolysaccharide-induced long-lasting hyperalgesia in the adult rats. Toxicology 2011, 279, 123–129.
   PubMed Web of Science ®Google Scholar
• Kitazawa, M., Cheng, D., Tsukamoto, M.R., Koike, M.A., Wes, P.D., Vasilevko, V., Cribbs, D.H., LaFerla, F.M. Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal ß-catenin pathway function in an Alzheimer’s disease model. J Immunol 2011, 187, 6539–6549.
   PubMed Web of Science ®Google Scholar
• Paradowski, B., Celczynska, D., Dobosz, T., Noga, L. Polymorphism 174 G/C of interleukin 6 gene in Alzheimer’s disease–preliminary report. Neurol Neurochir Pol 2008, 42, 312–315.
   PubMed Web of Science ®Google Scholar
• Butterworth, R.F. Pathophysiology of hepatic encephalopathy: The concept of synergism. Hepatol Res 2008, 38, S116–S121.
   PubMed Web of Science ®Google Scholar
• Chakrabarty, P., Jansen-West, K., Beccard, A., Ceballos-Diaz, C., Levites, Y., Verbeeck, C., Zubair, A.C., et al. Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J 2010, 24, 548–559.
   PubMed Web of Science ®Google Scholar
• Baranowska-Bik, A., Bik, W., Wolinska-Witort, E., Martynska, L., Chmielowska, M., Barcikowska, M., Baranowska, B. Plasma beta amyloid and cytokine profile in women with Alzheimer’s disease. Neuro Endocrinol Lett 2008, 29, 75–79.
   PubMed Web of Science ®Google Scholar
• Galimberti, D., Venturelli, E., Fenoglio, C., Guidi, I., Villa, C., Bergamaschini, L., Cortini, F., et al. Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer’s disease and frontotemporal lobar degeneration. J Neurol 2008, 255, 539–544.
   PubMed Web of Science ®Google Scholar
• Ciaramella, A., Bizzoni, F., Salani, F., Vanni, D., Spalletta, G., Sanarico, N., Vendetti, S., et al. Increased pro-inflammatory response by dendritic cells from patients with Alzheimer’s disease. J Alzheimers Dis 2010, 19, 559–572.
   PubMed Web of Science ®Google Scholar
• Klimkowicz-Mrowiec, A., Wolkow, P., Spisak, K., Maruszak, A., Styczynska, M., Barcikowska, M., Szczudlik, A., Slowik, A. Interleukin-6 gene (-174 C/G) and apolipoprotein E gene polymorphisms and the risk of Alzheimer disease in a Polish population. Neurol Neurochir Pol 2010, 44, 537–541.
   PubMed Web of Science ®Google Scholar
• He, M.X., Yang, W.L., Zhang, M.M., Lian, Y.J., Hua, H.Y., Zeng, J.S., Zhang, L.R. Association between interleukin-6 gene promoter -572C/G polymorphism and the risk of sporadic Alzheimer’s disease. Neurol Sci 2010, 31, 165–168.
   PubMed Web of Science ®Google Scholar
• Shibata, N., Ohnuma, T., Takahashi, T., Baba, H., Ishizuka, T., Ohtsuka, M., Ueki, A., Nagao, M., Arai, H. Effect of IL-6 polymorphism on risk of Alzheimer disease: genotype-phenotype association study in Japanese cases. Am J Med Genet 2002, 114, 436–439.
   PubMed Web of Science ®Google Scholar
• Crisby, M., Rahman, S.M., Sylvén, C., Winblad, B., Schultzberg, M. Effects of high cholesterol diet on gliosis in apolipoprotein E knockout mice. Implications for Alzheimer’s disease and stroke. Neurosci Lett 2004, 369, 87–92.
   PubMed Web of Science ®Google Scholar
• Famer, D., Wahlund, L.O., Crisby, M. Rosuvastatin reduces microglia in the brain of wild type and ApoE knockout mice on a high cholesterol diet; implications for prevention of stroke and AD. Biochem Biophys Res Commun 2010, 402, 367–372.
   PubMed Web of Science ®Google Scholar
• Famer, D., Crisby, M. Rosuvastatin reduces gliosis and the accelerated weight gain observed in WT and ApoE-/- mice exposed to a high cholesterol diet. Neurosci Lett 2007, 419, 68–73.
   PubMed Web of Science ®Google Scholar
• Yu, J.T., Tan, L., Song, J.H., Sun, Y.P., Chen, W., Miao, D., Tian, Y. Interleukin-18 promoter polymorphisms and risk of late onset Alzheimer’s disease. Brain Res 2009, 1253, 169–175.
   PubMed Web of Science ®Google Scholar
• Alboni, S., Montanari, C., Benatti, C., Blom, J.M., Simone, M.L., Brunello, N., Caggia, F., et al. Constitutive and LPS-regulated expression of interleukin-18 receptor beta variants in the mouse brain. Brain Behav Immun 2011, 25, 483–493.
   PubMed Web of Science ®Google Scholar
• Alboni, S., Cervia, D., Ross, B., Montanari, C., Gonzalez, A.S., Sanchez-Alavez, M., Marcondes, M.C., et al. Mapping of the full length and the truncated interleukin-18 receptor alpha in the mouse brain. J Neuroimmunol 2009, 214, 43–54.
   PubMed Web of Science ®Google Scholar
• Sugama, S., Cho, B.P., Baker, H., Joh, T.H., Lucero, J., Conti, B. Neurons of the superior nucleus of the medial habenula and ependymal cells express IL-18 in rat CNS. Brain Res 2002, 958, 1–9.
   PubMed Web of Science ®Google Scholar
• Wheeler, R.D., Culhane, A.C., Hall, M.D., Pickering-Brown, S., Rothwell, N.J., Luheshi, G.N. Detection of the interleukin 18 family in rat brain by RT-PCR. Brain Res Mol Brain Res 2000, 77, 290–293.
   PubMedGoogle Scholar
• Felderhoff-Mueser, U., Schmidt, O.I., Oberholzer, A., Bührer, C., Stahel, P.F. IL-18: a key player in neuroinflammation and neurodegeneration? Trends Neurosci 2005, 28, 487–493.
   PubMed Web of Science ®Google Scholar
• Conti, B., Park, L.C., Calingasan, N.Y., Kim, Y., Kim, H., Bae, Y., Gibson, G.E., Joh, T.H. Cultures of astrocytes and microglia express interleukin 18. Brain Res Mol Brain Res 1999, 67, 46–52.
   PubMedGoogle Scholar
• Bossù, P., Ciaramella, A., Salani, F., Bizzoni, F., Varsi, E., Di Iulio, F., Giubilei, F., et al. Interleukin-18 produced by peripheral blood cells is increased in Alzheimer’s disease and correlates with cognitive impairment. Brain Behav Immun 2008, 22, 487–492.
   PubMed Web of Science ®Google Scholar
• Segat, L., Milanese, M., Arosio, B., Vergani, C., Crovella, S. Lack of association between Interleukin-18 gene promoter polymorphisms and onset of Alzheimer’s disease. Neurobiol Aging 2010, 31, 162–164.
   PubMed Web of Science ®Google Scholar
• Engelborghs, S., De Brabander, M., De Crée, J., D’Hooge, R., Geerts, H., Verhaegen, H., De Deyn, P.P. Unchanged levels of interleukins, neopterin, interferon-gamma and tumor necrosis factor-alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type. Neurochem Int 1999, 34, 523–530.
   PubMed Web of Science ®Google Scholar
• Kawanokuchi, J., Mizuno, T., Takeuchi, H., Kato, H., Wang, J., Mitsuma, N., Suzumura, A. Production of interferon-gamma by microglia. Mult Scler 2006, 12, 558–564.
   PubMed Web of Science ®Google Scholar
• Fitzner, D., Schnaars, M., van Rossum, D., Krishnamoorthy, G., Dibaj, P., Bakhti, M., Regen, T., et al. Selective transfer of exosomes from oligodendrocytes to microglia by macropinocytosis. J Cell Sci 2011, 124, 447–458.
   PubMed Web of Science ®Google Scholar
• Baron, R., Nemirovsky, A., Harpaz, I., Cohen, H., Owens, T., Monsonego, A. IFN-gamma enhances neurogenesis in wild-type mice and in a mouse model of Alzheimer’s disease. FASEB J 2008, 22, 2843–2852.
   PubMed Web of Science ®Google Scholar
• Tobinick, E. Tumour necrosis factor modulation for treatment of Alzheimer’s disease: rationale and current evidence. CNS Drugs 2009, 23, 713–725.
   PubMed Web of Science ®Google Scholar
• Park, K.M., Bowers, W.J. Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal 2010, 22, 977–983.
   PubMed Web of Science ®Google Scholar
• Tobinick, E. Perispinal etanercept for treatment of Alzheimer’s disease. Curr Alzheimer Res 2007, 4, 550–552.
   PubMed Web of Science ®Google Scholar
• Tobinick, E. Perispinal etanercept for neuroinflammatory disorders. Drug Discov Today 2009, 14, 168–177.
   PubMed Web of Science ®Google Scholar
• Pardridge, W.M. Biologic TNFa-inhibitors that cross the human blood-brain barrier. Bioeng Bugs 2010, 1, 231–234.
   PubMedGoogle Scholar
• McCoy, M.K., Tansey, M.G. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 2008, 5, 45.
   PubMed Web of Science ®Google Scholar
• McAlpine, F.E., Lee, J.K., Harms, A.S., Ruhn, K.A., Blurton-Jones, M., Hong, J., Das, P., et al. Inhibition of soluble TNF signaling in a mouse model of Alzheimer’s disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis 2009, 34, 163–177.
   PubMed Web of Science ®Google Scholar
• Park, K.M., Yule, D.I., Bowers, W.J. Impaired TNF-alpha control of IP3R-mediated Ca2+ release in Alzheimer’s disease mouse neurons. Cell Signal 2010, 22, 519–526.
   PubMed Web of Science ®Google Scholar
• Kim, M.L., Zhang, B., Mills, I.P., Milla, M.E., Brunden, K.R., Lee, V.M. Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo. J Neurosci 2008, 28, 12052–12061.
   PubMed Web of Science ®Google Scholar
• Di Bona, D., Candore, G., Franceschi, C., Licastro, F., Colonna-Romano, G., Cammà, C., Lio, D., Caruso, C. Systematic review by meta-analyses on the possible role of TNF-alpha polymorphisms in association with Alzheimer’s disease. Brain Res Rev 2009, 61, 60–68.
   PubMedGoogle Scholar
• Wang, B., Zhou, S., Yang, Z., Xie, Y.C., Wang, J., Zhang, P., Lv, Z., et al. Genetic analysis of tumor necrosis factor-alpha (TNF-alpha) G-308A and Saitohin Q7R polymorphisms with Alzheimer’s disease. J Neurol Sci 2008, 270, 148–151.
   PubMed Web of Science ®Google Scholar
• Yang, L., Lu, R., Jiang, L., Liu, Z., Peng, Y. Expression and genetic analysis of tumor necrosis factor-alpha (TNF-alpha) G-308A polymorphism in sporadic Alzheimer’s disease in a Southern China population. Brain Res 2009, 1247, 178–181.
   PubMed Web of Science ®Google Scholar
• McCusker, S.M., Curran, M.D., Dynan, K.B., McCullagh, C.D., Urquhart, D.D., Middleton, D., Patterson, C.C., et al. Association between polymorphism in regulatory region of gene encoding tumour necrosis factor alpha and risk of Alzheimer’s disease and vascular dementia: a case-control study. Lancet 2001, 357, 436–439.
   PubMed Web of Science ®Google Scholar
• Buchhave, P., Zetterberg, H., Blennow, K., Minthon, L., Janciauskiene, S., Hansson, O. Soluble TNF receptors are associated with Aß metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiol Aging 2010, 31, 1877–1884.
   PubMed Web of Science ®Google Scholar
• Grell, M. Tumor necrosis factor (TNF) receptors in cellular signaling of soluble and membrane-expressed TNF. J Inflamm 1995, 47, 8–17.
   PubMedGoogle Scholar
• Cheng, X., Yang, L., He, P., Li, R., Shen, Y. Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer’s disease and non-demented patients. J Alzheimers Dis 2010, 19, 621–630.
   PubMed Web of Science ®Google Scholar
• He, P., Zhong, Z., Lindholm, K., Berning, L., Lee, W., Lemere, C., Staufenbiel, M., et al. Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer’s mice. J Cell Biol 2007, 178, 829–841.
   PubMed Web of Science ®Google Scholar
• Dolga, A.M., Nijholt, I.M., Ostroveanu, A., Ten Bosch, Q., Luiten, P.G., Eisel, U.L. Lovastatin induces neuroprotection through tumor necrosis factor receptor 2 signaling pathways. J Alzheimers Dis 2008, 13, 111–122.
   PubMed Web of Science ®Google Scholar
• Marchetti, L., Klein, M., Schlett, K., Pfizenmaier, K., Eisel, U.L. Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. J Biol Chem 2004, 279, 32869–32881.
   PubMed Web of Science ®Google Scholar
• Uberti, D., Cantarella, G., Facchetti, F., Cafici, A., Grasso, G., Bernardini, R., Memo, M. TRAIL is expressed in the brain cells of Alzheimer’s disease patients. Neuroreport 2004, 15, 579–581.
   PubMed Web of Science ®Google Scholar
• Hoffmann, O., Zipp, F., Weber, J.R. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation. J Mol Med 2009, 87, 753–763.
   PubMed Web of Science ®Google Scholar
• Cui, M., Wang, L., Liang, X., Ma, X., Liu, Y., Yang, M., Liu, K., et al. Blocking TRAIL-DR5 signaling with soluble DR5 reduces delayed neuronal damage after transient global cerebral ischemia. Neurobiol Dis 2010, 39, 138–147.
   PubMed Web of Science ®Google Scholar
• Uberti, D., Ferrari-Toninelli, G., Bonini, S.A., Sarnico, I., Benarese, M., Pizzi, M., Benussi, L., et al. Blockade of the tumor necrosis factor-related apoptosis inducing ligand death receptor DR5 prevents beta-amyloid neurotoxicity. Neuropsychopharmacology 2007, 32, 872–880.
   PubMed Web of Science ®Google Scholar
• Lambracht-Washington, D., Qu, B.X., Fu, M., Anderson, L.D. Jr, Stüve, O., Eagar, T.N., Rosenberg, R.N. DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer’s disease as it diminishes antigen-specific Th1 and Th17 cell proliferation. Cell Mol Neurobiol 2011, 31, 867–874.
   PubMed Web of Science ®Google Scholar
• Mizuno, T., Doi, Y., Mizoguchi, H., Jin, S., Noda, M., Sonobe, Y., Takeuchi, H., Suzumura, A. Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid-ß neurotoxicity. Am J Pathol 2011, 179, 2016–2027.
   PubMed Web of Science ®Google Scholar
• da Rocha, M.D., Viegas, F.P., Campos, H.C., Nicastro, P.C., Fossaluzza, P.C., Fraga, C.A., Barreiro, E.J., Viegas, C. Jr. The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer’s disease. CNS Neurol Disord Drug Targets 2011, 10, 251–270.
   PubMed Web of Science ®Google Scholar
• Montgomery, S.L., Mastrangelo, M.A., Habib, D., Narrow, W.C., Knowlden, S.A., Wright, T.W., Bowers, W.J. Ablation of TNF-RI/RII expression in Alzheimer’s disease mice leads to an unexpected enhancement of pathology: implications for chronic pan-TNF-a suppressive therapeutic strategies in the brain. Am J Pathol 2011, 179, 2053–2070.
   PubMed Web of Science ®Google Scholar
• Shi, J.Q., Shen, W., Chen, J., Wang, B.R., Zhong, L.L., Zhu, Y.W., Zhu, H.Q., et al. Anti-TNF-a reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res 2011, 1368, 239–247.
   PubMed Web of Science ®Google Scholar
• Minami, S.S., Sidahmed, E., Aid, S., Shimoji, M., Niikura, T., Mocchetti, I., Rebeck, G.W., et al. Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Aß/amyloid burden in a transgenic mouse model of Alzheimer’s disease. J Neuroinflammation 2010, 7, 57.
   PubMed Web of Science ®Google Scholar
• Koronyo-Hamaoui, M., Ko, M.K., Koronyo, Y., Azoulay, D., Seksenyan, A., Kunis, G., Pham, M., et al. Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9. J Neurochem 2009, 111, 1409–1424.
   PubMed Web of Science ®Google Scholar
• Town, T., Laouar, Y., Pittenger, C., Mori, T., Szekely, C.A., Tan, J., Duman, R.S., Flavell, R.A. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med 2008, 14, 681–687.
   PubMed Web of Science ®Google Scholar
• Lambert, K.E., Huang, H., Mythreye, K., Blobe, G.C. The type III transforming growth factor-ß receptor inhibits proliferation, migration, and adhesion in human myeloma cells. Mol Biol Cell 2011, 22, 1463–1472.
   PubMed Web of Science ®Google Scholar
• Basque, J., Martel, M., Leduc, R., Cantin, A.M. Lysosomotropic drugs inhibit maturation of transforming growth factor-beta. Can J Physiol Pharmacol 2008, 86, 606–612.
   PubMed Web of Science ®Google Scholar
• Mecha, M., Rabadán, M.A., Peña-Melián, A., Valencia, M., Mondéjar, T., Blanco, M.J. Expression of TGF-betas in the embryonic nervous system: analysis of interbalance between isoforms. Dev Dyn 2008, 237, 1709–1717.
   PubMed Web of Science ®Google Scholar
• Noguchi, A., Nawa, M., Aiso, S., Okamoto, K., Matsuoka, M. Transforming growth factor beta2 level is elevated in neurons of Alzheimer’s disease brains. Int J Neurosci 2010, 120, 168–175.
   PubMed Web of Science ®Google Scholar
• Peress, N.S., Perillo, E. Differential expression of TGF-beta 1, 2 and 3 isotypes in Alzheimer’s disease: a comparative immunohistochemical study with cerebral infarction, aged human and mouse control brains. J Neuropathol Exp Neurol 1995, 54, 802–811.
   PubMed Web of Science ®Google Scholar
• Tachi, N., Hashimoto, Y., Nawa, M., Matsuoka, M. TAG-1 is an inhibitor of TGFbeta2-induced neuronal death via amyloid beta precursor protein. Biochem Biophys Res Commun 2010, 394, 119–125.
   PubMed Web of Science ®Google Scholar
• Eslami, P., Johnson, M.F., Terzakaryan, E., Chew, C., Harris-White, M.E. TGF beta2-induced changes in LRP-1/T beta R-V and the impact on lysosomal A beta uptake and neurotoxicity. Brain Res 2008, 1241, 176–187.
   PubMed Web of Science ®Google Scholar
• Harris-White, M.E., Balverde, Z., Lim, G.P., Kim, P., Miller, S.A., Hammer, H., Galasko, D., Frautschy, S.A. Role of LRP in TGFbeta2-mediated neuronal uptake of Abeta and effects on memory. J Neurosci Res 2004, 77, 217–228.
   PubMed Web of Science ®Google Scholar
• Savvaki, M., Theodorakis, K., Zoupi, L., Stamatakis, A., Tivodar, S., Kyriacou, K., Stylianopoulou, F., Karagogeos, D. The expression of TAG-1 in glial cells is sufficient for the formation of the juxtaparanodal complex and the phenotypic rescue of tag-1 homozygous mutants in the CNS. J Neurosci 2010, 30, 13943–13954.
   PubMed Web of Science ®Google Scholar
• Savvaki, M., Panagiotaropoulos, T., Stamatakis, A., Sargiannidou, I., Karatzioula, P., Watanabe, K., Stylianopoulou, F., et al. Impairment of learning and memory in TAG-1 deficient mice associated with shorter CNS internodes and disrupted juxtaparanodes. Mol Cell Neurosci 2008, 39, 478–490.
   PubMed Web of Science ®Google Scholar
• Denaxa, M., Kyriakopoulou, K., Theodorakis, K., Trichas, G., Vidaki, M., Takeda, Y., Watanabe, K., Karagogeos, D. The adhesion molecule TAG-1 is required for proper migration of the superficial migratory stream in the medulla but not of cortical interneurons. Dev Biol 2005, 288, 87–99.
   PubMed Web of Science ®Google Scholar
• Soares, S., Traka, M., von Boxberg, Y., Bouquet, C., Karagogeos, D., Nothias, F. Neuronal and glial expression of the adhesion molecule TAG-1 is regulated after peripheral nerve lesion or central neurodegeneration of adult nervous system. Eur J Neurosci 2005, 21, 1169–1180.
   PubMed Web of Science ®Google Scholar
• Caraci, F., Spampinato, S., Sortino, M.A., Bosco, P., Battaglia, G., Bruno, V., Drago, F., et al. Dysfunction of TGF-ß1 signaling in Alzheimer’s disease: perspectives for neuroprotection. Cell Tissue Res 2012, 347, 291–301.
   PubMed Web of Science ®Google Scholar
• Tesseur, I., Zhang, H., Brecht, W., Corn, J., Gong, J.S., Yanagisawa, K., Michikawa, M., et al. Bioactive TGF-beta can associate with lipoproteins and is enriched in those containing apolipoprotein E3. J Neurochem 2009, 110, 1254–1262.
   PubMed Web of Science ®Google Scholar
• Ongali, B., Nicolakakis, N., Lecrux, C., Aboulkassim, T., Rosa-Neto, P., Papadopoulos, P., Tong, X.K., Hamel, E. Transgenic mice overexpressing APP and transforming growth factor-beta1 feature cognitive and vascular hallmarks of Alzheimer’s disease. Am J Pathol 2010, 177, 3071–3080.
   PubMed Web of Science ®Google Scholar
• Salins, P., He, Y., Olson, K., Glazner, G., Kashour, T., Amara, F. TGF-beta1 is increased in a transgenic mouse model of familial Alzheimer’s disease and causes neuronal apoptosis. Neurosci Lett 2008, 430, 81–86.
   PubMed Web of Science ®Google Scholar
• Papadopoulos, P., Ongali, B., Hamel, E. Selective in vivo antagonism of endothelin receptors in transforming growth factor-beta1 transgenic mice that mimic the vascular pathology of Alzheimer’s disease. Can J Physiol Pharmacol 2010, 88, 652–660.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Rodríguez, E., Sánchez-Juan, P., Mateo, I., Llorca, J., Infante, J., García-Gorostiaga, I., Berciano, J., Combarros, O. Serum levels and genetic variation of TGF-beta1 are not associated with Alzheimer’s disease. Acta Neurol Scand 2007, 116, 409–412.
   PubMed Web of Science ®Google Scholar
• Luedecking, E.K., DeKosky, S.T., Mehdi, H., Ganguli, M., Kamboh, M.I. Analysis of genetic polymorphisms in the transforming growth factor-beta1 gene and the risk of Alzheimer’s disease. Hum Genet 2000, 106, 565–569.
   PubMed Web of Science ®Google Scholar
• Mocali, A., Cedrola, S., Della Malva, N., Bontempelli, M., Mitidieri, V.A., Bavazzano, A., Comolli, R., et al. Increased plasma levels of soluble CD40, together with the decrease of TGF beta 1, as possible differential markers of Alzheimer disease. Exp Gerontol 2004, 39, 1555–1561.
   PubMed Web of Science ®Google Scholar
• King, V.R., Phillips, J.B., Brown, R.A., Priestley, J.V. The effects of treatment with antibodies to transforming growth factor beta1 and beta2 following spinal cord damage in the adult rat. Neuroscience 2004, 126, 173–183.
   PubMed Web of Science ®Google Scholar
• Lue, L.F., Kuo, Y.M., Beach, T., Walker, D.G. Microglia activation and anti-inflammatory regulation in Alzheimer’s disease. Mol Neurobiol 2010, 41, 115–128.
   PubMed Web of Science ®Google Scholar
• Lyons, A., McQuillan, K., Deighan, B.F., O’Reilly, J.A., Downer, E.J., Murphy, A.C., Watson, M., et al. Decreased neuronal CD200 expression in IL-4-deficient mice results in increased neuroinflammation in response to lipopolysaccharide. Brain Behav Immun 2009, 23, 1020–1027.
   PubMed Web of Science ®Google Scholar
• Chao, C.C., Molitor, T.W., Hu, S. Neuroprotective role of IL-4 against activated microglia. J Immunol 1993, 151, 1473–1481.
   PubMed Web of Science ®Google Scholar
• Szczepanik, A.M., Funes, S., Petko, W., Ringheim, G.E. IL-4, IL-10 and IL-13 modulate A beta(1–42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. J Neuroimmunol 2001, 113, 49–62.
   PubMed Web of Science ®Google Scholar
• Sholl-Franco, A., da Silva, A.G., Adão-Novaes, J. Interleukin-4 as a neuromodulatory cytokine: roles and signaling in the nervous system. Ann N Y Acad Sci 2009, 1153, 65–75.
   PubMed Web of Science ®Google Scholar
• Curbo, S., Gaudin, R., Carlsten, M., Malmberg, K.J., Troye-Blomberg, M., Ahlborg, N., Karlsson, A., et al. Regulation of interleukin-4 signaling by extracellular reduction of intramolecular disulfides. Biochem Biophys Res Commun 2009, 390, 1272–1277.
   PubMed Web of Science ®Google Scholar
• Kiyota, T., Okuyama, S., Swan, R.J., Jacobsen, M.T., Gendelman, H.E., Ikezu, T. CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer’s disease-like pathogenesis in APP+PS1 bigenic mice. FASEB J 2010, 24, 3093–3102.
   PubMed Web of Science ®Google Scholar
• Gambi, F., Reale, M., Iarlori, C., Salone, A., Toma, L., Paladini, C., De Luca, G., et al. Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1 beta levels and expression in peripheral blood mononuclear cells. J Clin Psychopharmacol 2004, 24, 314–321.
   PubMed Web of Science ®Google Scholar
• Colton, C.A., Mott, R.T., Sharpe, H., Xu, Q., Van Nostrand, W.E., Vitek, M.P. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflammation 2006, 3, 27.
   PubMed Web of Science ®Google Scholar
• Wang, S., Wang, R., Chen, L., Bennett, D.A., Dickson, D.W., Wang, D.S. Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer’s brain. J Neurochem 2010, 115, 47–57.
   PubMed Web of Science ®Google Scholar
• Walker, D.G., Dalsing-Hernandez, J.E., Campbell, N.A., Lue, L.F. Decreased expression of CD200 and CD200 receptor in Alzheimer’s disease: a potential mechanism leading to chronic inflammation. Exp Neurol 2009, 215, 5–19.
   PubMed Web of Science ®Google Scholar
• Park, K.W., Baik, H.H., Jin, B.K. Interleukin-4-induced oxidative stress via microglial NADPH oxidase contributes to the death of hippocampal neurons in vivo. Curr Aging Sci 2008, 1, 192–201.
   PubMedGoogle Scholar
• He, Y., Cui, J., Lee, J.C., Ding, S., Chalimoniuk, M., Simonyi, A., Sun, A.Y., et al. Prolonged exposure of cortical neurons to oligomeric amyloid-ß impairs NMDA receptor function via NADPH oxidase-mediated ROS production: protective effect of green tea (-)-epigallocatechin-3-gallate. ASN Neuro 2011, 3, e00050.
   PubMed Web of Science ®Google Scholar
• Ribizzi, G., Fiordoro, S., Barocci, S., Ferrari, E., Megna, M. Cytokine polymorphisms and Alzheimer disease: possible associations. Neurol Sci 2010, 31, 321–325.
   PubMed Web of Science ®Google Scholar
• Shibata, N., Ohnuma, T., Takahashi, T., Baba, H., Ishizuka, T., Ohtsuka, M., Ueki, A., et al. The effect of IL4 +33C/T polymorphism on risk of Japanese sporadic Alzheimer’s disease. Neurosci Lett 2002, 323, 161–163.
   PubMed Web of Science ®Google Scholar
• Fragoso, J.M., Vallejo, M., Alvarez-León, E., Delgadillo, H., Peña-Duque, M.A., Cardoso-Saldaña, G., Posadas-Romero, C., et al. Alleles and haplotypes of the interleukin 10 gene polymorphisms are associated with risk of developing acute coronary syndrome in Mexican patients. Cytokine 2011, 55, 29–33.
   PubMed Web of Science ®Google Scholar
• Jander, S., Pohl, J., D’Urso, D., Gillen, C., Stoll, G. Time course and cellular localization of interleukin-10 mRNA and protein expression in autoimmune inflammation of the rat central nervous system. Am J Pathol 1998, 152, 975–982.
   PubMed Web of Science ®Google Scholar
• Arosio, B., Mastronardi, L., Vergani, C., Annoni, G. Interleukin-10 promoter polymorphism in mild cognitive impairment and in its clinical evolution. Int J Alzheimers Dis 2010, 2010.
   PubMedGoogle Scholar
• Szczepanik, A.M., Ringheim, G.E. IL-10 and glucocorticoids inhibit Abeta(1-42)- and lipopolysaccharide-induced pro-inflammatory cytokine and chemokine induction in the central nervous system. J Alzheimers Dis 2003, 5, 105–117.
   PubMed Web of Science ®Google Scholar
• Zocchia, C., Spiga, G., Rabin, S.J., Grekova, M., Richert, J., Chernyshev, O., Colton, C., Mocchetti, I. Biological activity of interleukin-10 in the central nervous system. Neurochem Int 1997, 30, 433–439.
   PubMed Web of Science ®Google Scholar
• Combarros, O., Sánchez-Juan, P., Riancho, J.A., Mateo, I., Rodríguez-Rodríguez, E., Infante, J., García-Gorostiaga, I., et al. Aromatase and interleukin-10 genetic variants interactively modulate Alzheimer’s disease risk. J Neural Transm 2008, 115, 863–867.
   PubMed Web of Science ®Google Scholar
• McNaull, B.B., Todd, S., McGuinness, B., Passmore, A.P. Inflammation and anti-inflammatory strategies for Alzheimer’s disease–a mini-review. Gerontology 2010, 56, 3–14.
   PubMed Web of Science ®Google Scholar
• Yu, D, Corbett, B, Yan, Y, Zhang, GX, Reinhart, P, Cho, SJ, Chin, J Early cerebrovascular inflammation in a transgenic mouse model of Alzheimer’s disease. Neurobiol Aging, 2012, (In Press).
   Web of Science ®Google Scholar
• Jaturapatporn, D., Isaac, M.G., McCleery, J., Tabet, N. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer’s disease. Cochrane Database Syst Rev 2012, 2, CD006378.
   PubMed Web of Science ®Google Scholar
• van Exel, E., Eikelenboom, P., Comijs, H.C., Kurniawan, C., Frölich, M., Smit, J.H., Stek, M.L., et al. [The immune system and Alzheimer’s disease]. Tijdschr Psychiatr 2011, 53, 637–643.
   PubMedGoogle Scholar